The allogeneic cell therapy market, valued at USD 383 million in 2025, is projected to reach USD 650 million in 2026 and USD 6,013 million by 2035, representing a CAGR of 28% during the forecast period 2026 to 2035. Growth is being supported by expanding clinical pipelines, the potential for off-the-shelf availability, scalable batch manufacturing from qualified donor-derived cells and cell banks, advances in cell engineering, and increasing investment in automated manufacturing and commercializ...

The global cell therapy manufacturing market, valued at USD 4.8 billion in 2025, is estimated to reach USD 6.0 billion in 2026 and USD 12.5 billion by 2035, representing a CAGR of 8.53% during the forecast period 2026 to 2035. Growth is being supported by the expanding clinical pipeline, additional commercial launches, increasing manufacturing outsourcing, capacity investment and adoption of closed, automated and digitally connected production systems. According to American Society of Gene & Cel...

The global biologics fill finish manufacturing market, valued at USD 5.1 billion in 2025, is projected to reach USD 5.4 billion in 2026 and USD 9.4 billion by 2035, representing a CAGR of 6.33% during the forecast period 2026 to 2035. This growth is supported by expanding pipelines of antibodies, recombinant proteins, vaccines, other advanced biologics, and continued investment in automated aseptic fill and finish technologies to enhance manufacturing efficiency and product quality. In June 2026...

The global digital biomanufacturing market, valued at $2.4 billion in 2025, is projected to reach $2.8 billion in 2026 and $12.0 billion by 2035, representing a CAGR of 17.6% during the forecast period 2026 to 2035. Based on type of biologic manufactured, antibodies account for the largest share, at 70%, while the cell and gene therapies segment is expected to grow fastest, at a CAGR of 29%. In-house developers currently capture 65% of the market by end user, while contract manufacturers are exp...

The Europe prefilled syringes market, valued at USD 1.33 billion in 2025, is projected to reach USD 1.42 billion in 2026 and USD 2.19 billion by 2035, representing a CAGR of 4.9% during the forecast period 2026 to 2035.

The Europe antibody drug conjugates market, valued at USD 3.26 billion in 2025, is projected to reach USD 3.58 billion in 2026 and USD 4.98 billion by 2035, representing a CAGR of 3.7% during the forecast period 2026 to 2035. Antibody-drug conjugates (ADCs) combine the targeting specificity of a monoclonal antibody with potent cytotoxic payloads through specialized linkers, enabling selective delivery of anticancer agents to antigen-expressing tumor cells. For market sizing, the Europe scope in...

The global radiopharmaceutical manufacturing market, valued at USD 5.86 billion in 2025, is projected to reach USD 6.61 billion in 2026 and USD 13.79 billion by 2035, representing a CAGR of 8.5% during the forecast period from 2026 to 2035.

The North America antibody drug conjugates market, valued at USD 10.35 billion in 2025, is projected to reach USD 12.33 billion in 2026 and USD 17.73 billion by 2035, representing a CAGR of 4.1% during the forecast period 2026 to 2035. Over the years, ADC applications have expanded beyond hematological cancers into breast, lung, ovarian, urothelial, cervical and other solid tumors, with development increasingly moving into earlier lines of treatment. More than 370 ADC candidates had entered clin...

The global biostatistics and statistical programming services market, valued at USD 3.28 billion in 2025, is estimated at USD 3.52 billion in 2026 and is projected to reach USD 6.65 billion by 2035, representing a CAGR of 7.3% during the forecast period. Market growth is supported by rising statistical workload per clinical-development programs, flexible outsourcing of specialist biometrics capacity, and expanding regulatory and post-market statistical requirements. North America leads the globa...

The global artificial organs and bionics market, valued at USD 29.40 billion in 2025, is estimated at USD 31.46 billion in 2026 and is projected to reach USD 54.13 billion by 2035, representing a CAGR of 6.21% during the forecast period 2026 to 2035. Growth is being supported by sustained demand for long-duration organ support and the wider use of automated, wearable and restorative systems across chronic and irreversible conditions. Specialty clinics & rehabilitation centers represent the large...

The antibody drug conjugates market, valued at USD 15.47 billion in 2025, is projected to reach USD 18.57 billion in 2026 and USD 43.56 billion by 2035, representing a CAGR of 9.9% during the forecast period 2026 to 2035. Market growth is expected to be supported by the expanding global oncology therapeutics landscape, increasing commercialization of targeted cancer therapies, sustained industry investment, and the rising adoption of advanced treatment modalities across healthcare systems. Breas...

The global bioinformatics market was valued at USD 17.3 billion in 2025 and is estimated at USD 19.8 billion in 2026. It is projected to reach USD 52.6 billion by 2035, representing an 11.5% CAGR from 2026 to 2035. Expanding multi-omics workloads, production-grade analytical workflows and clinical interpretation needs are increasing demand for specialized bioinformatics platforms and services. Generalized knowledge management tools dominate the knowledge management tools segment in 2026; special...

The targeted alpha therapy market was valued at USD 0.22 billion in 2025 and is estimated to reach USD 0.20 billion in 2026. The market is projected to reach USD 4.39 billion by 2035, growing at a CAGR of 41.0% during 2026-2035. Market growth is expected to accelerate as late-stage Ac-225 and Pb-212 therapies advance toward commercialization alongside expanding radiopharmaceutical treatment and isotope infrastructure. Targeted alpha therapy (TAT) is attracting sustained oncology interest because...

The cytotoxic drugs and HPAPI manufacturing market, valued at USD 13.98 billion in 2025, is projected to grow to USD 15.59 billion in 2026 and USD 46.41 billion by 2035, representing a CAGR of 12.89% during the forecast period 2026 to 2035. The growth is being supported by rising demand for targeted oncology therapies, antibody-drug conjugates (ADCs), highly potent small molecules and other complex drug candidates that require specialized containment, process development and good manufacturing p...

The global peptide synthesis market, valued at USD 3.8 billion in 2025, is projected to reach USD 4.4 billion in 2026 and USD 7.0 billion by 2035, at a CAGR of 5.2% during the forecast period 2026 to 2035. This market size refers to the peptide API contract manufacturing opportunity rather than the broader market for peptide synthesizers, reagents, consumables or research-only peptide products. The market growth is being supported by the expanding pipeline of peptide therapeutics, rising commerc...

The global subcutaneous biologics market, valued at USD 250.6 billion in 2025, is projected to reach USD 267.6 billion in 2026 and USD 233.0 billion by 2035, during the forecast period 2026 to 2035. The long-term decline in value is primarily linked to patent expiry and revenue erosion across a number of currently marketed originator biologics, even as clinical activity, subcutaneous conversion programs and patient adoption continue to expand. In January 2026, FDA approved DARZALEX FASPRO® in c...

The global cell and gene therapy CRO market, valued at USD 1.9 billion in 2025, is estimated to reach USD 2.1 billion in 2026 and USD 3.5 billion by 2035, representing a CAGR of 5.7% during the forecast period. The market growth is being supported by the expanding pipeline of advanced therapies, increasing complexity of cell and gene therapy clinical development, growing outsourcing of specialized research activities and rising requirements for regulatory, clinical-operational, safety and data-m...

The global acute ischemic stroke therapeutics market, valued at USD 1,920 million in 2025, is projected to reach USD 2,077 million in 2026 and USD 3,917 million by 2035, representing a CAGR of 7.3% during the forecast period from 2026 to 2035. In terms of the type of molecule, biologics hold the highest share (nearly 55%) of the current market. By drug class, thrombolytics dominate the current acute ischemic stroke therapeutics market.

The peptide therapeutics contract manufacturing market was valued at USD 3.38 billion in 2025 and is estimated at USD 3.91 billion in 2026. It is projected to reach USD 10.79 billion by 2035, representing a CAGR of 11.94% during 2026-2035. Growth is being supported by the expanding commercial pipeline for peptide therapeutics and greater reliance on specialized external manufacturing capacity.

The global veterinary vaccines market, valued at USD 12.8 billion in 2025, is projected to reach USD 13.4 billion in 2026 and USD 22.0 billion by 2035, representing a CAGR of 5.69% during the forecast period 2026 to 2035. Around 60% of the known infectious diseases are zoonotic in origin (transmitted from animals to humans), responsible for 2.5 billion disease cases and 2.7 million human deaths every year, across the globe. Vaccination of animals helps protect animals as well as human population...